News
EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-Adhoc: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
EQS-News: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
EQS-News: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma’s Partner Takeda Reached Development Milestone
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma’s Partner Takeda Reached Development Milestone
EQS-News: Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
EQS-News: Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
EQS-Adhoc: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
EQS-Adhoc: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
EQS-News: Heidelberg Pharma reports on the results of the Annual General Meeting 2023
EQS-News: Heidelberg Pharma reports on the results of the Annual General Meeting 2023
EQS-News: Heidelberg Pharma appoints Chief Financial Officer
EQS-News: Heidelberg Pharma appoints Chief Financial Officer
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
EQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
EQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
EQS-Adhoc: Elanix Biotechnologies AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD
EQS-Adhoc: Elanix Biotechnologies AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD
EQS-News: Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:
EQS-News: Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:
EQS-News: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
EQS-News: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
EQS-News: Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
EQS-News: Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares